Business Wire

NY-EMENDO-BIO

17.5.2022 22:17:09 CEST | Business Wire | Press release

Share
Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting

Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.

Emendo presented pre-clinical data for the treatment of ELANE -related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo , showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.

“ELANE -based Severe Congenital Neutropenia, Emendo’s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,” said David Baram, Ph.D., President & CEO of Emendo Biotherapeutics. “We are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year’s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.”

Senior members of the Emendo Biotherapeutics R&D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research & Development Rafi Emmanuel, Ph.D. presented Emendo’s research on-site at the conference.

Session Presentation

Title: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia

Session Title: Gene Therapy for Immunologic Diseases
Session Date/Time: Tuesday May 17, 2022 3:45 PM - 5:30 PM
Presentation Time: 3:45pm - 4:00pm
Room: Room 202
Final abstract number: 482

Poster Presentations

Title: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy

Session Title: Cancer - Targeted Gene and Cell Therapy I
Session Date/Time: Monday May 16, 2022 5:30 PM - 6:30 PM
Poster Board Number: M-215
Room: Hall D
Final abstract number: 334

Title: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia

Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date/Time: Wednesday May 18, 2022 5:30 PM - 6:30 PM
Poster Board Number: W-125
Room: Hall D
Final abstract number: 999

Title: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification

Session Title: Gene Targeting and Gene Correction II
Session Date/Time: Tuesday May 17, 2022 5:30 PM - 6:30 PM
Poster Board Number: Tu-61
Room: Hall D
Final abstract number: 556

About Emendo Biotherapeutics

Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit www.emendobio.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Builds Future Workforce With Kansas’ First Aviation Youth Apprenticeship Program.30.9.2026 20:55:00 CEST | Press release

By combining education and industry experience, the new program creates early career opportunities for high school students while strengthening Kansas’ aviation workforce Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, is further bolstering the company’s efforts to build the next generation workforce as the first aviation company in Kansas to offer state-registered youth apprenticeships through the Kansas Office of Apprenticeships. The program expands career opportunities for high school students beginning at age 16 by providing paid, hands-on learning experiences that develop industry knowledge and career-ready skills while they complete their education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930818829/en/ Textron Aviation builds future workforce with Kansas’ first aviation youth apprenticeship program (Photo Credit: Textron Aviation). Textron Aviation is launching three state-registered youth apprenti

Thales and Landis+Gyr Enable Smarter, Remotely Managed Connectivity for Smart Meter Fleets30.9.2026 20:00:00 CEST | Press release

Thales, a global leader in cybersecurity and IoT connectivity management, and Landis+Gyr, a global energy technology leader grid edge intelligence and energy management, today announced a strategic collaboration to enable secure, scalable and future-ready cellular connectivity for smart meter deployments across North America. Thales will provide Landis+Gyr with eSIM technology and advanced IoT connectivity management to support the digital transformation of utilities by simplifying and securing remote management of smart meter fleets throughout their entire lifecycle. The solution - combined with Simetric’s single pane of glass - gives utilities a unified view of connectivity operations across their devices, enabling centralized monitoring and control of large-scale deployments to reduce field interventions and improve operational efficiency globally. As utilities modernize their infrastructure, smart meters are becoming an increasingly important part of the connected energy ecosystem.

135 Global Thought Leaders, Decision-Makers and Experts to Speak at World Green Economy Summit 202630.9.2026 17:45:00 CEST | Press release

Under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) and the World Green Economy Organization (WGEO) will organise the 12th World Green Economy Summit (WGES) on 21-22 October 2026 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930106199/en/ World Green Economy Summit 2025 (Photo: AETOSWire) Held under the theme ‘From Success to Scale: Showcasing the Green Economy’, the summit will host 135 speakers, including ministers, business leaders, government officials, decision-makers, experts and innovators from around the world. They will exchange insights and expertise while highlighting successful initiatives and models that can be scaled up to accelerate the transition to a green economy. “The World Green Economy Summit brings together gl

Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management30.9.2026 17:30:00 CEST | Press release

Boomi’s recognition as a Leader in API management reflects its vision and execution Boomi, the data activation company for AI, today announced it has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. We believe the recognition reflects Boomi’s sustained investment in Boomi API Management as the governance layer enterprises use to turn fragmented APIs into a trusted foundation for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930240079/en/ Boomi Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management Our Key Takeaways Boomi has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for API Management. A complimentary copy of the report is available here. Boomi is also a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service, where it has been named a Leader 12 consecutive times. Boomi API Management gives organizations one contro

Echodyne Awarded $250 Million JIATF-401 Counter-UAS Contract30.9.2026 17:00:00 CEST | Press release

Agreement creates a path to acquire high-accuracy MESA® radar for fixed, portable and on-the-move defense missions Echodyne, the radar platform company, today announced an indefinite-delivery/indefinite-quantity (IDIQ) contract supporting the Joint Interagency Task Force 401’s (JIATF-401) Domestic Shield program. The agreement has a $250 million ceiling and an ordering period of up to 36 months, providing a path to acquire counter-unmanned aircraft system (C-UAS) capabilities for force protection, base defense and counter-drone operations in the United States and abroad. As part of the agreement, Echodyne’s advanced MESA radars will be available for procurement on JIATF-401’s C-UAS Marketplace for U.S. and Allied Nations. At the center of Echodyne’s radar portfolio is MESA, its software-defined metamaterials electronically scanned array architecture. MESA combines precise electronic beam steering with a compact, solid-state design, delivering high-fidelity radar data without the size,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye